Unaudited Financial Results for the quarter ended 30th June 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 04 Aug 2026, 07:35 PM IST · BSE ID: 8f2340fe-5172-4381-945e-4e60db5de3ee
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its first quarter financial results, showing increased profit and revenue compared to the same period last year.
🤖 AI Summary
- Chemcrux Enterprises' Q1 FY27 standalone profit for the period was INR 137.43 lacs.
- Standalone revenue from operations for the quarter ended June 30, 2026, reached INR 2,193.81 lacs.
- Consolidated profit for the period was INR 50.52 lacs for the quarter ended June 30, 2026.
- The Board of Directors considered and approved the unaudited standalone and consolidated financial results.
- 1,07,700 Employee Stock Options were granted on May 15, 2026, under ESOP 2025 Scheme at Rs. 10 per share.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations
2,193.81 INR lacs
Standalone Profit for the period
137.43 INR lacs
135.12%
Consolidated Revenue from operations
2,193.82 INR lacs
Consolidated Profit for the period
50.52 INR lacs
444.60%
Employee Stock Options granted
1,07,700
🏢 How This Affects the Company
The company's revenue from operations increased to INR 2,193.81 lacs standalone and INR 2,193.82 lacs consolidated, indicating growth in its manufacturing and processing of Bulk Drug Intermediates business.
Standalone profit for the period increased to INR 137.43 lacs and consolidated profit to INR 50.52 lacs, improving overall profitability compared to the previous year's corresponding quarter.
The grant of 1,07,700 Employee Stock Options suggests an ongoing strategy to incentivize eligible employees, potentially impacting future employee benefits expense.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as these results reflect the company's financial health and operational performance for the quarter ended June 30, 2026.
🔍
Management Signal
The approval of unaudited results and the grant of ESOPs signal management's ongoing commitment to business operations and employee incentives.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained profit growth and revenue trends.
Updates on the impact of ESOP 2025 scheme on employee benefits expense.
Any further announcements regarding operational expansion or business developments.
MEDIUM RISK
While YoY profits are strong, QoQ declines in key metrics present some short-term volatility.
💡 Investor Takeaway
Chemcrux Enterprises reported Q1 FY27 standalone profit for the period of INR 137.43 lacs, marking a 135.12% increase from INR 58.45 lacs in Q1 FY26. Consolidated profit for the period rose to INR 50.52 lacs from INR 9.27 lacs in the prior year period.
⚖️ Strengths & Concerns
✅ Positives
- Standalone profit for the period increased by 135.12% YoY to INR 137.43 lacs for the quarter ended June 30, 2026.
- Consolidated profit for the period rose by 444.60% YoY to INR 50.52 lacs for the quarter ended June 30, 2026.
⚠️ Concerns
- Standalone Revenue from operations decreased by 9.64% QoQ to INR 2,193.81 lacs from INR 2,428.14 lacs.
- Consolidated Profit Before Tax decreased by 63.18% QoQ to INR 98.17 lacs from INR 267.00 lacs.
📅 Company Track Record
Previous filing on May 7, 2026, informed about the Board meeting to approve FY26 results and consider a dividend. This filing reports the unaudited Q1 FY27 results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Chemcrux Enterprises' standalone net profit for Q1 FY27?
Chemcrux Enterprises reported a standalone profit for the period of INR 137.43 lacs for the quarter ended June 30, 2026, which is a 135.12% increase compared to INR 58.45 lacs in Q1 FY26.
What was Chemcrux Enterprises' consolidated revenue from operations in Q1 FY27?
The consolidated revenue from operations for Chemcrux Enterprises was INR 2,193.82 lacs for the quarter ended June 30, 2026.
How many Employee Stock Options were granted by Chemcrux Enterprises?
Chemcrux Enterprises granted 1,07,700 Employee Stock Options under the ESOP 2025 Scheme on May 15, 2026, at an exercise price of Rs. 10 per share.
What was the consolidated profit for Chemcrux Enterprises in Q1 FY27?
The consolidated profit for the period for Chemcrux Enterprises was INR 50.52 lacs for the quarter ended June 30, 2026, marking a 444.60% increase from INR 9.27 lacs in Q1 FY26.
Questions based on this BSE filing only. For information purposes.